Targeted intraoperative radiotherapy tumour bed boost during breast conserving surgery after neoadjuvant chemotherapy in HER2 positive and triple negative breast cancer.

CONCLUSION: Although survival estimates trended towards favouring TARGIT-IORT, no significant differences could be observed and the significantly positive result for OS favoring TARGIT-IORT in the whole cohort of 116 patients could not be reproduced in this subset analysis of patients with TN and HER2 positive tumours. This may be contributable to the limited number of patients but may also indicate that effects seen in the whole cohort were mainly driven by ER and/or PR positive and HER2 negative tumours. Most importantly, non-inferiority of TARGIT-IORT as an intraoperative boost could be reproduced in these high-risk patients.
PMID: 28155607 [PubMed - as supplied by publisher]

Source: Reviews on Recent Clinical Trials - January 31, 2017 Category: Cancer & Oncology Authors: Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching PA, Untch M, Bulsara M, Vaidya JS, Liedtke C Tags: Rev Recent Clin Trials Source Type: research